Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user is seeking advice on preserving hair follicles at Norwood stage 6 or 7 while waiting for new treatments. They are considering using treatments like Minoxidil, finasteride, or RU58841.

The conversation discusses the role of DHT in male hair loss and the effectiveness of treatments like Finasteride, which reduces DHT, and RU58841, which blocks DHT from binding to scalp receptors. The user debates the trade-offs between maintaining hair and having a healthy endocrine system, suggesting RU58841 might allow for both.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

A 21-year-old is experiencing hair loss and is unsure whether to choose minoxidil or finasteride. They prefer oral treatments and are leaning towards finasteride despite concerns about side effects and family opposition.

Mixing minoxidil and alfatradiol in one bottle may affect their effectiveness due to potential stability issues. It's recommended to apply them separately for full benefits.

Oral minoxidil is considered unsafe due to severe side effects and requires close medical supervision, while oral finasteride is viewed as safe and effective. There is debate over the fear-mongering around finasteride and the downplaying of minoxidil's risks, with some users advocating for proper health screenings before use.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

The user plans to try finasteride again due to past side effects, considering a gradual increase starting at 0.25 mg every 5 days to reach 0.5 mg/day. They seek advice on a tapering schedule to minimize side effects.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The user is considering adding topical dutasteride and increasing their oral minoxidil dose to 5mg, and is currently using oral finasteride, oral and topical minoxidil, derma stamping, tretinoin, and nizoral as part of their hair loss treatment regimen.

A 19-year-old is using 5% topical minoxidil, 1.25 mg finasteride, ketoconazole, and a dermaroller for hair regrowth, noticing improvement in the frontal area. Another user suggests adding oral minoxidil and maintaining a consistent routine, emphasizing the importance of stress management and a healthy diet for better results.

The user is considering switching from finasteride to RU-58841 for hair loss due to side effects and is concerned about its safety around cats. They are also seeking dosage suggestions and alternatives like pyrilutamide.

RU58841 is debated for hair loss treatment, with concerns about safety and effectiveness. Some users prefer premixed solutions despite higher costs, while others report issues with DIY methods and potential health risks.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.

The conversation discusses the anticipation of Chinese manufacturers producing Clascoterone 5% before its full approval in 2027. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

Finasteride is effective for hair loss but can cause sexual dysfunction and mental health issues in some users, leading to a polarized debate on its risks. Some switch to alternatives like Dutasteride or topical treatments to avoid side effects.

Dermatologists use treatments like oral minoxidil, finasteride, and RU58841 for male-pattern baldness, considering side effects and patient preferences. Photobiomodulation is noted as mildly effective but costly, while PRP is debated for its effectiveness compared to microneedling.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

Using both finasteride and dutasteride for hair loss is debated, with some seeing it as beneficial during transition, while others find it redundant and risky. Oral minoxidil raises concerns about blood pressure, with a preference for topical use and microneedling for better results.

Increasing Dutasteride dosage from 0.5mg to 1.5mg may inhibit more scalp DHT, but the exact benefit is unclear. Combining Dutasteride with leftover Finasteride might not provide additional benefits.

The conversation discusses dissatisfaction with current hair loss treatments that mainly focus on DHT blockers like finasteride and dutasteride. Alternative treatments mentioned include RU58841, pyrilutamide, minoxidil, rosemary oil, and future possibilities like hair cloning.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

A user's experience with taking finasteride and dutasteride to address hair loss, and the proactive approach they took to maintain their hair. They discussed using these medications every day and transitioning between them.

A user's plan to use Zix and topical finasteride (5AR inhibitors) for hair loss, followed by blood testing before/after. The user has suggested creating a fund to cover part of the cost of their blood tests. Replies to their post discuss the effectiveness of the treatments.

Finasteride worked better for frontal scalp hair loss, while dutasteride helped the crown and mid-scalp but worsened the frontal area. The user shared personal experiences and invited open dialogue.

The user is considering switching from 0.25 mg oral finasteride to a 0.3% topical finasteride solution to see if it's more effective for hair loss. They also inquire about using 2.5 mg oral minoxidil with a 6% topical minoxidil solution.

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.